iBio, Inc. Files 8-K Report

TL;DR

iBio filed an 8-K on 6/17/25 - standard update.

AI Summary

On June 17, 2025, iBio, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as iBioPharma, Inc., is incorporated in Delaware and headquartered in New York, NY.

Why It Matters

This filing provides an update on iBio, Inc.'s corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K report, which typically contains standard corporate information and does not indicate any unusual or significant events.

Key Numbers

• 001-35023 — Commission File Number (Identifies the company's filing with the SEC)
• 26-2797813 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• iBio, Inc. (company) — Registrant
• June 17, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• New York, NY (location) — Business address
• iBioPharma, Inc. (company) — Former company name

FAQ

From the Filing

0001420720-25-000027.txt : 20250618 0001420720-25-000027.hdr.sgml : 20250618 20250618072217 ACCESSION NUMBER: 0001420720-25-000027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250617 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250618 DATE AS OF CHANGE: 20250618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251055126 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250617x8k.htm 8-K iBio, Inc._June 17, 2025 0001420720 false 0001420720 2025-06-17 2025-06-17 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road, Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 8.01. Other Events. ​ As previously disclosed, iBio, Inc. (the “Company”) issued a promissory note (the “Note”) in the principal amount of $1,500,000 on June 19, 2023 with Safi Biotherapeutics Inc. (“Safi’), which Note matures on June 19, 2025, unless extended by mutual consent of the Company and Safi.  On June 17, 2025, the Company and Safi agreed to extend the maturity date of the Note to June 19, 2026 provided that all accrued inter